Aptissen Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
43
- Latest Deal Type
-
Later Stage VC
- Investors
-
1
Aptissen General Information
Description
Developer of injectable medical products designed to reduce the pain and discomfort caused by osteoarthritis. The company's products are used for osteoarthritis with a combination of hyaluronic acid and a high concentration of sorbitol, enabling patients to have mobility recovery and quick pain relief.
Contact Information
Website
www.aptissen.comCorporate Office
- Chemin du
- Champ des Filles 36A
- 1228 Plan-Les-Ouates
- Switzerland
Corporate Office
- Chemin du
- Champ des Filles 36A
- 1228 Plan-Les-Ouates
- Switzerland
Aptissen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 01-Feb-2023 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | 01-Jun-2014 | Completed | Clinical Trials - General | |||
| 1. Spin-Off | 01-Jan-2013 | Completed | Startup |
Aptissen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aptissen Patents
Aptissen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2595252-T3 | Aqueous sterile injectable formulation based on cross-linked hyaluronic acid and hydroxyapatite for therapeutic use | Active | 08-Oct-2012 | ||
| CA-2885884-A1 | Injectable sterile aqueous formulation based on crosslinked hyaluronic acid and on hydroxyapatite, for therapeutic use | Inactive | 08-Oct-2012 | ||
| EP-2903591-A1 | Injectable sterile aqueous formulation based on crosslinked hyaluronic acid and on hydroxyapatite, for therapeutic use | Active | 08-Oct-2012 | ||
| EP-2903591-B1 | Injectable sterile aqueous formulation based on crosslinked hyaluronic acid and on hydroxyapatite, for therapeutic use | Inactive | 08-Oct-2012 | ||
| US-20150238525-A1 | Injectable sterile aqueous formulation based on crosslinked hyaluronic acid and on hydroxyapatite, for therapeutic use | Inactive | 08-Oct-2012 | A61K33/42 |
Aptissen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aptissen Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EFI Lake Geneva Ventures | Venture Capital | Minority |
Aptissen FAQs
-
When was Aptissen founded?
Aptissen was founded in 2013.
-
Where is Aptissen headquartered?
Aptissen is headquartered in Plan-Les-Ouates, Switzerland.
-
What is the size of Aptissen?
Aptissen has 43 total employees.
-
What industry is Aptissen in?
Aptissen’s primary industry is Therapeutic Devices.
-
Is Aptissen a private or public company?
Aptissen is a Private company.
-
What is Aptissen’s current revenue?
The current revenue for Aptissen is .
-
How much funding has Aptissen raised over time?
Aptissen has raised $56.2K.
-
Who are Aptissen’s investors?
EFI Lake Geneva Ventures has invested in Aptissen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
